NCT06187064

Combination Primary Care and Prevention Services for Women Who Inject Drugs and Exchange Sex in Seattle, Washington

Completed NA Results posted Last updated 20 February 2026

What this trial tests

NA trial testing Mobile Van Clinic in Opioid Use Disorder in 50 participants. Completed in 12 March 2025.

Timeline

18 March 2024

Primary endpoint
12 March 2025

12 March 2025

Quick facts

Lead sponsor	University of Washington
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	health services research
Enrollment	50
Start date	18 March 2024
Primary completion	12 March 2025
Estimated completion	12 March 2025
Sites	1 location across United States

Drugs / interventions tested

• Mobile Van Clinic

Conditions studied

• Opioid Use Disorder — all drugs for Opioid Use Disorder →
• HIV Infections — all drugs for HIV Infections →
• Chlamydia — all drugs for Chlamydia →
• Gonorrhea — all drugs for Gonorrhea →

Sponsor

University of Washington

Who can join

18 and older, any sex, with Opioid Use Disorder or HIV Infections. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Evaluate Uptake of Pre-exposure Prophylaxis (PrEP) Primary · 6 months

Proportion of participants who initiate PrEP

Group	Value	95% CI
Study Cohort	10

Evaluate Uptake of Medications for Opioid Use Disorder (MOUD) Primary · 6 months

Proportion of participants who initiate MOUD

Group	Value	95% CI
Study Cohort	21

Adverse events — posted to ClinicalTrials.gov

Time frame: Up to 6 months post-enrollment.. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Study Cohort

Serious: 13/50 (26%)

Deaths: 2/50

Serious adverse events (1 terms)

Reaction	System	Study Cohort
Hospitalizations	General disorders	—

Most-reported serious reactions: Hospitalizations.

Data from ClinicalTrials.gov NCT06187064 adverse events section.

Sponsor's own description

The investigators will implement a non-randomized observational clinical trial that will include a pop-up clinic for women who inject drugs (WWID) near venues for exchange sex and drug use in north Seattle. The pop-up clinic will be housed within a van and serve as a research extension of the SHE Clinic, a Harborview Medical Center run clinic for women who exchange sex and use drugs in north Seattle. Through the implementation of the pop-up clinic, the investigators will aim to assess:

1. The impact of the pop-up clinic on uptake and sustained use of HIV pre-exposure prophylaxis (PrEP) and medications for opioid use disorder (MOUD) among WWID.
2. The impact of point of care (POC) sexually transmitted infection (STI) testing on STI treatment completion rates.
3. The acceptability and feasibility of providing HIV prevention care for WWID and exchange sex in a pop-up van clinic.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.